Valeant Pharma, Canada’s most valuable company, has more upside: Morgan Stanley


Days after the company made headlines by passing RBC as Canada’s most valuable company, Valeant Pharmaceuticals (TSX:VRX, TSE:VRX, NYSE:VRX) got a vote of confidence from an American bank that thinks it has more upside. Morgan Stanley analyst David Risinger Monday increased his target price on Valeant from from $235 to $284, maintaining his “Overweight” rating […]

Innovative Breast Cancer Techniques Being Developed at Canadian Light Source


Dr. Saroj Kumar and his team at the University of Saskatchewan are developing a new non-invasive technique to screen and treat breast cancer at its earliest stages using the Canadian Light Source, a synchrotron facility that allows researchers to study the microstructure and chemical properties of materials. In November, Kumar and his fellow researchers published […]

Pressure on Patient Home Monitoring’s stock should soon subside, says Mackie


A conference call to introduce new execs of Patient Home Monitoring (TSXV:PHM, CVE:PHM) should help calm the market’s somewhat frazzled nerves on the story, says Mackie Research Capital analyst Russell Stanley. Shares of Patient Home Monitoring have been under pressure since July 13, when the company announced it had appointed Casey Hoyt as CEO and […]

Convalo Health rises on second quarter results


Shares of Convalo Health (TSXV:CXV, CVE:CXV) are up today after the company reported its second quarter results. Convalo posted EBITDA of $458,695 on revenue of $2.31-million, up 93% quarter-over-quarter. But CEO Michael Dalsin said they didn’t quite reflect the company’s current trajectory. “Although we’re very happy to see the tremendous organic revenue and EBITDA growth […]

Canada still falling short of herd immunity, reveals new report

The smallpox vaccine diluent in a syringe alongside a vial of Dryvax dried smallpox vaccine.

A newly released study reveals Canada is falling short of a key level of community immunization. Today, Stats Canada released the 2013 Childhood National Immunization Coverage Survey. It revealed that about 89% of two-year-olds had received the recommended number of immunizations against measles, mumps and rubella and about 77% of two-year-olds had received the required […]

Resverlogix rises after closing $50-million financing

Resverlogix CEO Donald McCaffrey.

Shares of Resverlogix (TSX:RVX, TSE:RVX) are up today after the company announced it has completed a previously announced private placement. Under the terms of the agreement, Shenzhen Hepalink Pharmaceutical will buy 13.27-million units at $2.67 for proceeds of $35-million, bringing its ownership of Resverlogix to 12.63%. Eastern Capital, which owns nearly 20% of Resverlogix, will […]

TSO3 is undervalued, says M Partners analyst Pearlstein

sterizone VP4

TSO3 (TSX:TOS, TSE:TOS) has an innovative product that could disrupt incumbents in the sterilization space, says M Partners analyst Daniel Pearlstein. In a research report to clients today, Pearlstein initiated coverage of TSO3 with a “Buy” rating and a one year target price of $3.50, implying a return of 129% at the time of publication. […]

5 Questions With Cameron Groome of Avivagen


Ottawa-based Avivagen Inc. (TSXV:VIV) has been developing a natural replacement for antibiotics in livestock feed, as well as a drug-based means for animal sterilization that would eliminate the need for a surgical procedure. Having already implemented the non-antibiotic technology in two pet supplements, the company is looking to expand into the livestock feed market. With […]

Intellijoint HIP to Be Launched This Afternoon at MaRS Discovery District Event


Waterloo-based developer of surgical smart tools Intellijoint Surgical will be launching its flagship product, the intellijonit HIP, in Toronto today at the MaRS Discovery District at 2:30 p.m. The intellijoint HIP, an FDA cleared and Health Canada licensed miniature smart tool, is a smart surgical instrument that allows orthopaedic surgeons to control several key measurements […]

5 Questions With David Hall of RepliCel Life Sciences

RepliCel CEO David Hall

Vancouver-based RepliCel Life Sciences (TSXV:RP) concentrated on hair regeneration until 2011, participating in the $3 billion annual male pattern baldness industry. But when the far-reaching effects of its solution became apparent to its founders, RepliCel began expanding its offer to apply the technique of using cell therapy to encourage the healing of damaged or injured […]